People

 AZTherapies has named Ernest D. Penachio to the newly created position of VP of Manufacturing Operations and CMC to oversee clinical and pre-commercial manufacturing, scale-up, and CMC content development for the company's ALZT-OP1 inhaled cromolyn/oral ibuprofen combination therapy for the treatment of Alzheimer's disease, which is in Phase 3 development. … [Read more...] about AZTherapies names Ernest Penachio VP of Manufacturing Operations and CMC

Inhaled drug developer Pulmatrix has announced the appointment of Nocion Therapeutics CEO Rick Batycky to its board of directors. Batycky was a founder of Civitas Therapeutics, which developed Inbrija inhaled levodopa and which was acquired by Acorda in 2014. Prior to serving as Chief Scientific Officer at Civitas and then Chief Technology Officer at Acorda, Batycky … [Read more...] about Rick Batycky joins Pulmatrix board of directors

Liquidia Technologies has announced the appointment of AbbVie VP of Global Commercial Development Katie Rielly-Gauvin to its board of directors for a term that will extend until company's 2020 annual meeting. Prior to her position at AbbVie, Rielly-Gauvin held various executive positions at Johnson & Johnson companies over a number of therapeutic areas. In … [Read more...] about Liquidia adds Katie Rielly-Gauvin to its board of directors

Inhaled nitric oxide developer Third Pole Therapeutics has announced the appointment of Bill Athenson as its new Chief Executive Officer, succeeding founding CEO David Zapol. Athenson most recently served as CEO of Three Lakes Partners; his previous experience includes 13 years as the VP, Global Sales, Marketing and Business Development at Nanosphere Inc. In … [Read more...] about Third Pole Therapeutics names Bill Athenson as CEO

Inhaled drug developer Vectura has announced the appointment of former Catalent executive Will Downie as CEO and Executive Director. Downie was most recently Senior VP, Global Sales and Marketing at Catalent and previously served in various roles at GE Healthcare, Amersham Health, and Quintiles. In July 2019, Vectura announced that it would focus its R&D … [Read more...] about Vectura names Will Downie as CEO and Executive Director

Contract manufacturer Experic, which offers a variety of services related to dry powder inhalers, has named Sherry Ann D’Iorio as Executive Director of Business Development. D'Iorio was most recently Senior Account Director of Business Development at PPD and has previously held positions at a number of life sciences companies, including Worldwide Clinical Trials, … [Read more...] about Experic names Sherry Ann D’Iorio as Executive Director of Business Development

Texas-based Pulmotect, which is developing an inhaled immune stimulant for the treatment of respiratory diseases, has announced the appointment of Colin Broom as CEO. Broom was most recently CEO of Nabriva Therapeutics and previously served as Chief Scientific Officer at ViroPharma and in various roles at Amgen, Aventis, and GSK. Pulmotect is a spin out of … [Read more...] about Pulmotect names Colin Broom as CEO

Inhalation Sciences AB (ISAB) has announced that former ExScale Bio CEO Manoush Masarrat, who has been a member of the ISAB board of directors since January 2019, will succeed Lena Heffler as ISAB CEO. In addition to his most recent position as CEO of ExScale Bio, Masarrat has also served in sales and marketing roles at a number of companies, including Medical Vision, … [Read more...] about Inhalation Sciences names Manoush Masarrat as CEO

Milestone Pharmaceuticals has announced the appointment of former Sanofi executive Amit Hasija as Chief Financial Officer and Executive VP of Corporate Development. Milestone's etripamil, an intranasal calcium channel antagonist, is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia (PSVT). Hasija was most recently Chief Business … [Read more...] about Milestone Pharmaceuticals announces appointment of Amit Hasija as CFO and Executive VP of Corporate Development